Search tool

The EMCDDA Drug policy profiles aim to describe some of the main characteristics of national drug policies in Europe and beyond. The profiles do not attempt to assess these policies, but instead...

The General report of activities is an annual publication providing a detailed progress report of the EMCDDA’s activities over a 12-month period. It catalogues the Centre’s achievements in each area of its...

Drugnet Europe, the EMCDDA's quarterly newsletter, provides regular information on the Agency's activities to a broad readership. In this issue: over 40 new drugs reported in 2010; HIV in the European region...

This report presents the results and outlines the key achievements for 2010 on the information exchange, risk-assessment and control of new psychoactive substances. In 2010, 41 new psychoactive substances were officially notified...

This publication presents the summary findings and the conclusions of the risk assessment on mephedrone, carried out by the EMCDDA’s extended Scientific Committee, with participation of additional experts from the European Commission...

This report is based on work commissioned by the EMCDDA in 2009. It examines differences in methods and results between general population surveys conducted in a single context (focusing exclusively on substance...

Drugnet Europe, the EMCDDA's quarterly newsletter, provides regular information on the Agency's activities to a broad readership. In this issue: mephedrone ban across the EU; Poland passes new law to control ‘head...

The EMCDDA receives stable funding under Commission budget line B3-441 of the general budget of the European Union. Each year, a preliminary draft budget is presented by the Centre's Director to the...

The 2011 work programme takes forward activities begun in 2010 to implement the EMCDDA’s three-year strategy (2010–12). Key themes of this strategy are the consolidation of core data, investment in more complex...

The main goal of the First European conference on drug supply indicators was to launch the work needed to establish a set of technically sound and sustainable indicators for monitoring drug markets...